Literature DB >> 302479

Agammaglobulinemia with arthritis and celiac disease developing after infectious mononucleosis. Follow-up study of a case.

M Lanning, K Kouvalainen, S Similä, V Raunio.   

Abstract

A previously healthy 2 1/2-year-old boy from a healthy family developed agammaglobulinemia with arthritis 3 months after infectious mononucleosis (IM). The response of serum immunoglobulins at the initial stage of IM was typical, with greatly elevated IgM and a positive IM-specific heterophil antibody test. A secondary celiac disease was diagnosed one year after IM. Considering the serum immunoglobulin levels and the normal half-lives of IgM and IgG, it seems very probable that the synthesis of immunoglobulins ceased about one month after the onset of IM. The role of suppresor T-cells in the development of acquired secondary agammaglobulinemia is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 302479     DOI: 10.3109/inf.1977.9.issue-2.18

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  4 in total

1.  Clinical and immunologic analyses of 103 patients with common variable immunodeficiency.

Authors:  C Cunningham-Rundles
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

2.  Coeliac disease with severe hypogammaglobulinaemia.

Authors:  A D Webster; G Slavin; M Shiner; T A Platts-Mills; G L Asherson
Journal:  Gut       Date:  1981-02       Impact factor: 23.059

3.  T cell heterogeneity in patients with common variable immunodeficiency as assessed by abnormalities of T cell subpopulations and T cell receptor gene analysis.

Authors:  F Pandolfi; L Trentin; J E San Martin; J T Wong; J T Kurnick; R A Moscicki
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

4.  Persistent hypogammaglobulinemia following mononucleosis in boys is highly suggestive of X-linked lymphoproliferative disease--report of three cases.

Authors:  B Hügle; P Suchowerskyj; H Hellebrand; B Adler; M Borte; U Sack; U Schulte Overberg-Schmidt; N Strnad; J Otto; A Meindl; V Schuster
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.